CLICK4HP Archives

Health Promotion on the Internet

CLICK4HP@YORKU.CA

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
John Nicholson <[log in to unmask]>
Reply To:
Health Promotion on the Internet <[log in to unmask]>
Date:
Mon, 31 Oct 2011 10:28:32 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (60 lines)
Apologies for cross posting.

The World Bank's Global HIV/AIDS Program and the Office of HIV/AIDS at
USAID are co-hosting a debate series that discusses the constantly
changing dynamics of HIV/AIDS, and our collective response. The sixth
debate, entitled “Treatment as Prevention” will feature expert
panelists arguing for and against the proposition:

“Countries should spend a majority of what is likely to be a flat or
even declining HIV prevention budget on 'treatment as prevention'.”

Recent studies have shown that persons living with HIV who are on
antiretroviral treatment, are much less infectious and therefore much
less likely to transmit HIV to others. The HPTN-052 randomised study
found a 96% reduction in HIV transmission from an HIV-infected person to
his/her sexual partner, for the 76% of cases where intra-couple
transmission took place. Results suggesting similar levels of
acquisition risk reduction were reported in the 2010 Partners in
Prevention study. What do these latest results mean for HIV prevention
programming? Should “treatment as prevention” become HIV prevention
policy in countries? For all persons or only for adults in long-term
sexual partnerships? Does the type of epidemic (i.e. concentrated,
mixed, generalized) matter? How feasible are these interventions? Is it
ethical not to implement them, given that their efficacy between
long-term sexual partners is known? Should prevention resources be
diverted away from other interventions, such as behavior change efforts,
to fund increased ART? Who will pay for costs of the increased volumes
of drugs? Do we know enough about the side-effects or about drug
resistance? These questions and others related to treatment as
prevention will be discussed.

You can join the conversation in person at the World Bank, attend at a
videoconference site, or participate via webcast. Questions may be sent
to [log in to unmask] 

You must RSVP by Friday, 4 November 2011.

Date & Time
Thursday, 10 November 2011
09:00-11:00 am EDT or 15:00-17:00 Central African Time

Locations
The World Bank Preston Auditorium, Washington DC, USA
Video conference facilities throughout Africa
Webcast

For more information and to register, visit the AIDSTAR-One Website:
http://j.mp/sVyTZx


John Nicholson | Knowledge Management/Communications Manager
202.276.0624| Direct
703.528.7474 | Office
 
John Snow Inc. 
 
 

To manage subscriptions/passwords, or view archives, go to http://listserv.yorku.ca/archives/click4hp.html . [log in to unmask] is run in collaboration with Health Nexus: http://www.healthnexus.ca/index_eng.php

ATOM RSS1 RSS2